Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.

Author: AstrupArne, DayWesley W, EngeliStefan, FinerNick, JordanJens, NarkiewiczKrzysztof

Paper Details 
Original Abstract of the Article :
Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011567/

データ提供:米国国立医学図書館(NLM)

Phentermine and Topiramate: A New Hope for Obesity Treatment

Obesity is a major health concern worldwide, and the search for safe and effective weight loss treatments continues. This study delves into the cardiovascular risks and benefits of a combination therapy using phentermine and topiramate extended-release.

A Safer Option for Weight Management

The researchers reviewed data on the long-term use of this combination therapy and found that it may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.

Balancing Weight Loss with Cardiovascular Health

This study reminds us of the importance of finding a balance between weight management and cardiovascular health. If you're considering weight loss medications, it's crucial to discuss your individual risks and benefits with your doctor. Just like a camel adapts to survive in the desert, finding the right approach for your health journey is key.

Dr.Camel's Conclusion

This research provides encouraging evidence for the potential of this drug combination in treating obesity, especially in patients with lower cardiovascular risk. Further research is needed to understand the long-term effects of this combination therapy, but it offers a ray of hope in the ongoing fight against obesity.
Date :
  1. Date Completed 2015-02-19
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

24621808

DOI: Digital Object Identifier

PMC4011567

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.